Q-omics provides the consensus-scored CSN2 profile across patient tissues and cancer cell-line models. CSN2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CSN2 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, CSN2 protein abundance shows 6,917 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight UVM, BRCA, and OV as cancer lineages where CSN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSN2 survival associations across molecular data types. CSN2 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSN2 RNA expression–survival associations across cancer types. High CSN2 expression shows unfavorable associations in UVM, KIRC, ACC, TGCT and SKCM, but favorable associations in PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CSN2 RNA expression.
This table summarizes CSN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 2. The strongest signals are observed in BRCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CSN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSN2 shows lower tumor expression in BRCA, HNSC and STAD and higher tumor expression in LIHC, LUSC and LUAD. The BRCA box plot shows higher CSN2 RNA expression in normal versus tumor tissue (log2 FC = −0.941, t-test p < 0.001).
This table shows molecular features associated with CSN2 in patient tissues and cancer cell lines. In patient samples, CSN2 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set. In cancer cell lines, CSN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and KIDNEY.
